The U.S. Food and Drug Administration approved LEQEMBI IQLIK (lecanemab-irmb) as a subcutaneous injection on July 13, 2026, making it the first Alzheimer’s disease treatment that patients can start administering themselves at home. This represents a fundamental shift in how early-stage Alzheimer’s patients access disease-modifying therapy. Previously, patients interested in lecanemab had to visit an infusion center every two weeks for 18 months just to receive the initiation phase of treatment—a barrier that prevented many people from beginning therapy at all.
The at-home formulation uses a once-weekly autoinjector that delivers 500 mg as two 250-mg injections, each taking roughly 15 seconds to administer. Patients receive training from their healthcare provider on proper injection technique and aseptic handling before they begin self-administering at home, ensuring safety and consistency. After 18 months on the initiation dose, patients can choose to transition to maintenance therapy given either intravenously every four weeks or via subcutaneous injection weekly. This approval addresses one of the most significant barriers to Alzheimer’s treatment initiation in the United States. For someone in the early stages of cognitive decline, the commitment to biweekly infusions for a year and a half created a practical obstacle that deterred many patients and caregivers from even attempting to start a disease-modifying drug, regardless of its clinical benefits.
Table of Contents
- What Changed From the Intravenous Version of Lecanemab?
- Understanding Dosing, Administration, and Training
- Clinical Evidence—What the Numbers Actually Mean
- Safety Profile—Brain Swelling and Microhemorrhages
- Cost, Insurance, and Access in 2026
- Who Qualifies for At-Home Lecanemab?
- Timeline, Access, and Next Steps
What Changed From the Intravenous Version of Lecanemab?
The previous intravenous formulation of lecanemab required patients to sit in an infusion center for hours every two weeks during the 18-month initiation phase, with the IV line delivering medication directly into the bloodstream. The at-home subcutaneous version eliminates that requirement, allowing patients to self-inject at home after a single training session with a healthcare provider. The convenience difference is stark: instead of 36 biweekly clinic visits spread across 18 months, a patient now receives training once and then self-administers a quick subcutaneous injection in their kitchen or bedroom. The economic model also shifts substantially.
Annual treatment costs for the at-home subcutaneous version are modeled at approximately $20,020 at list price for 52 weekly injections of the 360-mg autoinjector formulation, compared to roughly $28,270 annually for the IV regimen when accounting for average patient dosing. Health-economic projections suggest that over four years, the at-home regimen could generate $72,891 to $80,925 in savings per patient compared to IV administration, driven largely by reduced administrative burden and downstream quality-of-life costs associated with fewer clinic visits. This shift matters because the clinical efficacy is identical—both formulations deliver the same active ingredient, lecanemab, and both demonstrated the same 27% reduction in cognitive decline over 18 months in clinical trials. The difference is entirely about delivery and accessibility.
Understanding Dosing, Administration, and Training
The at-home initiation regimen begins with 500 mg once weekly, split into two 250-mg injections delivered via prefilled autoinjectors. Each injection takes approximately 15 seconds to complete. A healthcare provider must train the patient and any caregiver on proper injection technique before home administration begins, covering how to prepare the injection site, how to hold and use the autoinjector, and how to maintain sterile handling of the medication. After 18 months of the weekly 500-mg initiation phase, patients transition to maintenance therapy.
they have two options: continue with subcutaneous injections at 360 mg weekly, or switch to intravenous infusions of 10 mg/kg body weight every four weeks. Some patients choose to continue the subcutaneous route for simplicity; others prefer the less-frequent IV maintenance schedule if they have reliable infusion center access and want to reduce injection frequency. One important limitation: patients must have a healthcare provider available for initial training and ongoing monitoring. While the self-injection itself becomes routine after the first week or two, the medication still requires a prescription, regular check-ins with a neurologist or primary care physician, and typically at least annual MRI imaging to screen for amyloid-related imaging abnormalities. Patients with severe injection anxiety, cognitive impairment that prevents them from following injection procedures, or caregiving situations where consistent supervision is unavailable may face challenges with self-administration, even if the injection technique itself is simple.
Clinical Evidence—What the Numbers Actually Mean
The clinical trial data comes from CLARITY-AD, a Phase 3 randomized controlled trial comparing lecanemab to placebo in people with mild cognitive impairment or mild dementia due to amyloid-pathology-confirmed Alzheimer’s disease. Over 18 months, lecanemab recipients showed a 27% reduction in cognitive decline compared to placebo, as measured by the Clinical Dementia Rating Scale Sum of Boxes—a standard neuropsychological assessment used across Alzheimer’s research. Translated into practical terms over longer treatment windows: three years of lecanemab treatment resulted in a 1.01-point reduction in cognitive decline, and four years of treatment resulted in a 1.75-point reduction.
These numbers may sound modest, but they represent meaningful slowing of a neurodegenerative process. For a 65-year-old newly diagnosed with mild cognitive impairment due to Alzheimer’s, a 1.75-point four-year advantage could mean the difference between needing full-time care assistance at age 69 versus maintaining functional independence for one or two additional years. It is important to note that lecanemab does not reverse cognitive decline or restore lost memory—it slows the rate at which cognitive decline progresses. For someone experiencing early cognitive changes, this slowing effect can defer the need for assisted living, preserve independence in managing finances or household responsibilities, and extend the window during which meaningful engagement with family and community remains possible.
Safety Profile—Brain Swelling and Microhemorrhages
Lecanemab’s safety profile includes a significant risk category called ARIA, or amyloid-related imaging abnormalities. These are changes visible on MRI that reflect how the brain tissue responds to the breakdown of amyloid plaques. In the CLARITY-AD trial, 12.6% of patients taking lecanemab showed ARIA-E (amyloid-related imaging abnormalities-edema), or brain swelling. An additional 14% of patients showed ARIA-H (amyloid-related imaging abnormalities-microhemorrhages), or microscopic bleeding in the brain tissue. Most ARIA events are asymptomatic—patients experience no symptoms and discover them only because they have routine MRI imaging as part of their treatment monitoring.
However, symptomatic ARIA can cause cognitive fluctuations, confusion, headaches, or vision changes, and in rare cases, serious complications. The trial data showed 21.3% of lecanemab recipients experienced an adverse event of any kind, compared to 9.3% of placebo recipients, a more than twofold difference. The presence of ARIA underlies why lecanemab is approved only for mild cognitive impairment or mild dementia due to Alzheimer’s disease, not for moderate or advanced disease. Patients on the therapy require regular brain MRI monitoring—typically annually during the first two years and then as clinically indicated—to catch any ARIA changes before they cause symptoms. Patients with certain genetic risk factors, particularly carriers of the APOE4 gene variant (which is associated with higher Alzheimer’s risk), have higher rates of ARIA and therefore require closer monitoring and discussion with their neurologist about the risk-benefit calculation before starting treatment.
Cost, Insurance, and Access in 2026
LEQEMBI IQLIK carries a list price of $385 per 360-mg prefilled autoinjector. Since the at-home initiation regimen uses 500-mg weekly injections (two 250-mg injectors per week for 18 months, then potentially transitioning to 360-mg injectors at the maintenance phase), the annual cost at list price equals $20,020 for one year of initiation-phase treatment. This is substantially lower than the roughly $28,270 annual cost of the IV formulation for an average-weight patient. The practical out-of-pocket cost depends entirely on insurance coverage.
Medicare will likely cover lecanemab with the standard Part D medication copay and deductible structures; commercial insurance coverage varies by plan. Eisai and Biogen, the co-developers and co-distributors, typically offer patient assistance programs for uninsured or underinsured patients, though those programs have income cutoffs and waiting periods. The expected commercial launch in late August 2026 will occur through specialty pharmacies, which manage delivery, insurance prior-authorization, and patient education rather than through standard retail pharmacies. For a patient with commercial insurance and a $50 copay per injection, the out-of-pocket cost would be approximately $2,600 annually, with any remaining balance potentially covered by insurance up to their deductible and maximum out-of-pocket limits. For a Medicare beneficiary, costs would be determined by their specific Part D plan and whether they receive copay assistance through manufacturer programs.
Who Qualifies for At-Home Lecanemab?
Lecanemab is approved specifically for people in the early stages of Alzheimer’s disease: those with mild cognitive impairment or mild dementia confirmed to have amyloid pathology in their brains. The amyloid requirement is important—the drug targets amyloid plaques, so it works only in people who actually have amyloid accumulation. This requires either an amyloid PET scan, a tau PET scan, or an amyloid and phosphorylated tau cerebrospinal fluid test through lumbar puncture (spinal tap).
Patients who are already on the IV formulation of lecanemab and tolerating it well can switch to the at-home subcutaneous version. Patients with moderate or advanced dementia are not candidates because the ARIA risks increase with greater cognitive impairment, making the safety profile unacceptable for that population. Additionally, patients with certain neurological conditions, severe injection phobia, or cognitive impairment severe enough that they cannot follow injection instructions safely are not appropriate candidates despite meeting other criteria.
Timeline, Access, and Next Steps
The commercial launch of LEQEMBI IQLIK is scheduled for late August 2026, meaning the medication will become available through specialty pharmacies starting approximately six to eight weeks after the FDA approval date. Patients interested in starting lecanemab should schedule an appointment with a neurologist or cognitive specialist to discuss whether they are eligible—this requires a cognitive assessment and confirmation of amyloid pathology. The entire evaluation process typically takes several weeks to schedule appointments and complete testing.
Once a patient is deemed eligible and a prescription is written, the specialty pharmacy handles insurance authorization and delivery of the first shipment of autoinjectors, usually within one to two weeks. The patient then schedules a training appointment with an infusion center, neurologist’s office, or specialty pharmacy clinical team to learn proper injection technique and aseptic handling. Training usually takes 30 to 60 minutes, after which patients begin their once-weekly self-injections at home. Patients should expect to continue regular neurologist appointments and annual MRI screening to monitor for ARIA throughout their treatment.
- —
